Results showed budesonide/glycopyrronium/formoterol fumarate 320/28.8/9.6μg met all primary endpoints in both KALOS and LOGOS. Topline data were announced from two ...

It set out significant changes to previous treatment approaches, including replacing the use of SABA alone with combined inhaled corticosteroid (ICS)/formoterol inhalers. There were also several ...

Each therapy area's strategy is to build business around one key product group. In Respiratory, the key product group is Easyhaler® product portfolio, in CNS entacapone products and in Women's Health ...

As formoterol works as quickly and as effectively as salbutamol, it can provide that symptom relief and is therefore a viable alternative to salbutamol. When combined with an inhaled steroid, ...

The literature highlights that dose emission from an Easyhaler ® is fairly consistent irrespective of the inhalation technique used by patients of all age groups. Clinical studies have shown ...